Preservation of renal endothelial integrity and reduction of renal edema by aprotinin does not preserve renal perfusion and function following experimental cardiopulmonary bypass

Nicole A. M. Dekker1,2,3*, Anoek L. I. van Leeuwen1,2,3, Matijs van Meurs4,5, Jill Moser4,5, Jeannette E. Pankras6, Nicole N. van der Wel6, Hans W. Niessen7, Marc G. Vervloet8, Alexander B. A. Vonk2, Peter L. Hordijk3, Christa Boer1 and Charissa E. van den Brom1,3,9

Abstract

Background: Acute kidney injury is a severe complication following cardiopulmonary bypass (CPB) and is associated with capillary leakage and microcirculatory perfusion disturbances. CPB-induced thrombin release results in capillary hyperpermeability via activation of protease-activated receptor 1 (PAR1). We investigated whether aprotinin, which is thought to prevent thrombin from activating PAR1, preserves renal endothelial structure, reduces renal edema and preserves renal perfusion and reduces renal injury following CPB.

Methods: Rats were subjected to CPB after treatment with 33,000 KIU/kg aprotinin (n = 15) or PBS (n = 15) as control. A secondary dose of 33,000 KIU/kg aprotinin was given 60 min after initiation of CPB. Cremaster and renal microcirculatory perfusion were assessed using intravital microscopy and contrast echography before CPB and 10 and 60 min after weaning from CPB. Renal edema was determined by wet/dry weight ratio and renal endothelial structure by electron microscopy. Renal PAR1 gene and protein expression and markers of renal injury were determined.

Results: CPB reduced cremaster microcirculatory perfusion by 2.5-fold (15 (10–16) to 6 (2–10) perfused microvessels, \( p < 0.001 \)) and renal perfusion by 1.6-fold (202 (67–599) to 129 (31–292) au/sec, \( p = 0.03 \)) in control animals. Both did not restore 60 min post-CPB. This was paralleled by increased plasma creatinine (\( p < 0.01 \)), neutrophil gelatinase-associated lipocalin (NGAL; \( p = 0.003 \)) and kidney injury molecule-1 (KIM-1; \( p < 0.01 \)). Aprotinin treatment preserved cremaster microcirculatory perfusion following CPB (12 (7–15) vs. 6 (2–10) perfused microvessels, \( p = 0.002 \)), but not renal perfusion (96 (35–313) vs. 129 (31–292) au/s, \( p > 0.9 \)) compared to untreated rats. Aprotinin treatment reduced endothelial gap formation (0.5 ± 0.5 vs. 3.1 ± 1.4 gaps, \( p < 0.0001 \)), kidney wet/dry weight ratio (4.6 ± 0.2 vs. 4.4 ± 0.2, \( p = 0.046 \)), and fluid requirements (3.9 ± 3.3 vs. 7.5 ± 3.0 ml, \( p = 0.006 \)) compared to untreated rats. In addition, aprotinin treatment...
reduced tubulointerstitial neutrophil influx by 1.7-fold compared to untreated rats (30.7 ± 22.1 vs. 53.2 ± 17.2 neutrophil influx/section, p = 0.009). No differences were observed in renal PAR1 expression and plasma creatinine, NGAL or KIM-1 between groups.

**Conclusions:** Aprotinin did not improve renal perfusion nor reduce renal injury during the first hour following experimental CPB despite preservation of renal endothelial integrity and reduction of renal edema.

**Keywords:** Cardiopulmonary bypass, Microcirculation, Capillary permeability, Acute kidney injury, Renal perfusion, Edema

**Background**

Acute kidney injury (AKI) is one of the most serious complications following cardiac surgery with cardiopulmonary bypass (CPB). AKI occurs in 2 to 40% of the patients depending on studied population and classification used [1] and is associated with prolonged hospitalization and postoperative morbidity [2]. AKI is also considered as strong risk factor for mortality after cardiac surgery with mortality rates up to 70% in patients with AKI requiring dialysis [3]. Despite its well-known impact on postoperative outcome and health care costs [4], therapeutic strategies to effectively prevent or treat AKI remain to be identified.

To date, AKI following cardiac surgery with CPB is mainly ascribed to renal hypoperfusion and renal hypoxia [5, 6]. Previously, we showed that CPB induces microcirculatory perfusion disturbances, [7] which remain disturbed for at least three days postoperatively [8]. The etiology of these microcirculatory perfusion disturbances and AKI are multifactorial [9]. For example, CPB-associated hemodilution and changes in vascular resistance reduce renal oxygen delivery [10, 11]. In addition, initiation of CPB induces a systemic inflammatory response [12], resulting in renal neutrophil influxes and renal edema following capillary leakage [13]. In particular, renal capillary leakage and edema formation seem to play a central role in the development of microcirculatory perfusion disturbances and AKI. Previous results from our group revealed that therapeutic inhibition of capillary leakage improved cremaster microcirculatory perfusion and renal function following experimental CPB [14, 15].

Besides inducing a systemic inflammatory response, CPB is associated with the generation of thrombin, which is an independent risk factor for the development of AKI [16]. Thrombin can activate a wide range of receptors, but has extremely high affinity for protease-activated receptor 1 (PAR1) which is present on both platelets and endothelial cells [17, 18]. As a result, thrombin generation following CPB is associated with activation of coagulation and increased vascular permeability through endothelial activation. These results suggest that thrombin release could contribute to CPB-associated capillary leakage and AKI and therefore prevention of thrombin-induced activation of PAR1 could be of interest to protect renal function during cardiac surgery with CPB [19].

Aprotinin is a serine protease inhibitor associated with anti-inflammatory and anti-fibrinolytic properties during cardiac surgery [20, 21]. Despite the controversy regarding its effect during cardiac surgery on postoperative morbidity, aprotinin exerts a variety of interesting mechanistic actions, which have scarcely been
investigated and may be of additional interest for its use during cardiac surgical procedures. Although aprotinin was initially introduced for clinical use in cardiac surgery patients to prevent blood loss and preserve platelet function, it has also been shown to prevent thrombin from cleaving and activating PAR1 on both platelets [21, 22] and endothelial cells [23, 24]. Therapeutically targeting the thrombin/PAR1 pathway may provide a unique treatment strategy to reduce both the pro-thrombotic and pro-inflammatory state to preserve organ function following CPB [19]. Therefore, we investigated whether aprotinin reduces renal edema and thereby protects renal perfusion and renal function following experimental CPB.

Materials and methods

Animals
All procedures were approved by the Institutional Animal Care and Use Committee of the VU University, the Netherlands (Animal welfare number: AVD1140020172144; local protocol number: 2144-ANES 17-01), and conducted following the EU Directive (2010/63EU) on the protection of vertebrate animals used for experimental and other scientific purposes and are reported in accordance with the ARRIVE guidelines on animal research. [25].

Male Wistar rats of 375–425 g (Charles River Laboratories, Brussels, Belgium) were randomly assigned to undergo cardiopulmonary bypass (CPB) with aprotinin treatment (CPB + AP, n = 15) or phosphate buffered solution (PBS) as control (CPB, n = 15) for measurement of cremaster and renal perfusion (Fig. 1a). Rats were culled by blood withdrawal under 5.0% isoflurane inhalation 60 min after weaning from CPB. Blood was protracted from the femoral arterial line in approximately 1 min using a 10 mL syringe. Kidneys were isolated and blood and urine samples were collected and stored at −80 °C for additional molecular analyses.

An additional group of sham rats (Sham, n = 9) were included to investigate the effect of CPB on renal outcome parameters. The sham procedure was identical to the CPB groups except for initiation and weaning of CPB, but including heparin, rocuronium bromide and protamine administration.

Aprotinin treatment
All tubes containing either aprotinin or PBS were prepared at the start of the study and randomly numbered. Aprotinin (Trasylol®, Nordic Pharma, Baarn, The Netherlands) was dissolved in PBS and 33.000 KIU/kg was administered via the jugular vein 20 min prior to CPB and a secondary dose of 33.000 KIU/kg was given 60 min after initiation of CPB. Equal volumes of PBS were administered in control rats. Investigators performing the experiments were blinded for group allocation. Group allocation was revealed when data acquisition and analyses were completed.

Anesthesia and surgical preparation
All animals were anesthetized as previously reported [14, 15] with 4.0% isoflurane (Ivax Farma, Haarlem, The Netherlands) in oxygen. Following endotracheal intubation with a 16G catheter (Venflon Pro, Becton Dickinson, Helsingborg, Sweden), lungs were mechanically ventilated (UMV-03, UNO Roestvaststaal BV, Zevenaar, The Netherlands;
Fig. 1 Schematic overview and perioperative hemodynamics. Rats were randomized to undergo cardiopulmonary bypass with PBS (CPB control, n = 15) or cardiopulmonary bypass with aprotinin treatment (CPB + AP, n = 15). AP or PBS were administered after baseline measurements were performed and a secondary dose was given 60 min after onset of CPB. Microcirculatory perfusion measurements in the cremaster muscle (yellow circles) were performed directly after the surgical preparation before onset of CPB (baseline), 10 min after initiation of CPB (10 min CPB), 60 min after initiation of CPB (60 min CPB), 10 min after weaning from CPB (10 min post-CPB) and 60 min after weaning from CPB (60 min post-CPB). Renal perfusion measurements (red circles) were performed before onset of CPB (baseline), 10 min after weaning from CPB (10 min post-CPB) and 60 min after weaning from CPB (60 min post-CPB). Plasma was collected at baseline, 60 min after initiation of CPB (60 min CPB) and 60 min after weaning from CPB (60 min post-CPB). Rats were culled 60 min after weaning from CPB and urine samples and kidneys were stored for further analyses (a). Mean arterial pressure (b) and hematocrit levels (c) in rats during and following cardiopulmonary bypass (CPB; white boxes; n = 15) or CPB with aprotinin treatment (CPB + AP; red boxes; n = 15). Boxes and whiskers represent median, interquartile and full range, *p < 0.05 CPB vs. CPB baseline, #p < 0.05 CPB vs. CPB + AP.
PEEP 2–4 cm H₂O, respiratory rate of 60–65 breaths/min, tidal volume ~ 10 ml/kg) and anesthesia was maintained with 1.5–2.0% isoflurane in oxygen-enriched air (40% O₂/60% N₂). Additionally, fentanyl boluses (12 µg/kg) were administered every 30–40 min. Respiratory rate was adjusted based on blood gas values to maintain pH and partial pressure of carbon dioxide within physiological limits. Depth of anesthesia was continuously monitored and adjusted if necessary based on heart rate and mean arterial pressure. A 22G catheter (Venflon Pro, Becton Dickinson, Helsingborg, Sweden) was placed in the caudal (tail) artery for continuous measurements of arterial blood pressure and blood withdrawal for blood gas analysis and hematocrit measurements (ABL80, Radiometer, Copenhagen, Denmark). Arterial blood pressure, ECG and heart rate were continuously recorded using PowerLab software (PowerLab 8/35, Chart 8.0; AD Instruments Pty, Ltd., Castle Hill, Australia).

The left cremaster muscle was isolated and prepared for cremaster perfusion measurements as previously described [14, 15]. Heparin (500 IU/kg, LEOPharma, Amsterdam, The Netherlands) was administered followed by cannulation of the right femoral artery with a 20G catheter (Arterial Cannula, Becton Dickinson, Helsingborg, Sweden) for arterial inflow of the CPB circuit. The right jugular vein was catheterized with a 20G catheter (Venflon Pro, Becton Dickinson, Helsingborg, Sweden) for administration of aprotinin or PBS, and the administration of microbubbles for contrast enhanced echography (CEUS). Further information can be found in the Additional file 1.

Cardiopulmonary bypass

The protocol for CPB was performed as previously described [14, 15]. In summary, the CPB circuit consisted of an open venous reservoir, a roller pump (Pericor SF70, Verder, Haan, Germany), and an oxygenator-heat exchanger with a three-layer hollow fiber membrane for gas exchange (Ing. M. Humbs, Valley, Germany) (Fig. 1). A 1.0-mm-diameter arterial line (LectroCath, Vygon, Ecouen, France) was connected to the femoral inflow catheter. The circuit was primed with 10 ml of 6% hydroxyethyl starch (HES; Voluven, Fresenius Krabi, Halden, Norway). During CPB, CO₂ and O₂ pressures of the oxygenator membrane of the CPB circuit were adjusted based on blood gas values to maintain pH and partial pressure of carbon dioxide within physiological limits. Additional doses of 6% hydroxyethyl starch (1 mL bolus; 6%HES; Voluven, Fresenius Krabi, Halden, Norway) were administrated when necessary to maintain target CPB flow rates > 150 ml/kg/min. Hematocrit levels were checked to avoid excessive fluid resuscitation. Moreover, boluses of phenylephrine (0.1 mg) were administered if necessary to maintain mean arterial pressure above 50 mmHg to sustain organ perfusion pressure. Detailed information can be found in the Additional file 1.

Cremaster microcirculatory perfusion

Microcirculatory perfusion measurements were performed using a 10 × objective on an intravital microscope (Axiotech Vario 100HD, Zeiss, Oberkochen, Germany) connected to a digital camera (scA640, Basler, Ahrensburg, Germany) with a final magnification of 640x, as described previously [14, 15]. Briefly, three regions of the microvasculature (vessels up to 25 µm diameter) in the cremaster muscle with adequate perfusion quality were selected during baseline. These exact predefined regions were followed throughout
the experiment: after surgical preparation of the cremaster muscle before onset of CPB (baseline), 10 min after initiation of CPB (10 min CPB), 60 min after initiation of CPB (60 min CPB), 10 min after weaning from CPB (10 min post-CPB) and 60 min after weaning from CPB (60 min post-CPB) (Fig. 1a).

Microcirculatory perfusion analyses were performed offline by an investigator who was blinded for treatment allocation. Analyses were performed as previously described by categorizing capillaries based on flow patterns as follows: perfused (continuous blood flow), intermittently perfused (blood flow was reversed or arrested for at least 50% of the time) and non-perfused capillaries (no flow). Pearson coefficient of the intra- and inter-observer correlation of the number of perfused vessels were 0.982 ($p < 0.0001$) and 0.959 ($p < 0.0001$), respectively.

Renal perfusion

Contrast enhanced echography was performed as previous described [26] with a Vevo 2100 Imaging System and MS 250 Nonlinear Contrast Imaging transducer (VisualSonics Inc, Toronto, Canada). Microbubbles were continuously infused via the jugular vein with a rate of 150 µl/min and the right kidney was visualized in the longitudinal plane before onset of CPB (baseline), 10 min after weaning from CPB (10 min post-CPB) and 60 min after weaning from CPB (60 min post-CPB) (Fig. 1).

For each measurement, regions of interest were drawn in the renal cortex by an investigator who was blinded for treatment allocation. Renal signal intensities were fitted ($Y = Y_0 + (A - Y_0) \cdot (1 - \exp(-\beta \cdot x))$) for calculation of renal vascular blood volume ($A$) and renal vascular filling velocity ($\beta$), which corresponds to renal blood exchange rate. The estimate of renal perfusion was calculated as the product of $A$ and $\beta$. Detailed information can be found in the Additional file 1.

Renal edema

Renal tissue was harvested at the end of the experiment under terminal anesthesia. Wet tissue was weighed and dried at 70 °C. After 24 h, dry tissue was weighed and renal wet-to-dry weight (W/D) ratio was calculated as estimate for tissue water content.

Electron microscopy

Renal tissue ($n = 3–4$ per group) was used for analysis of renal cortical capillary endothelial ultrastructure [14]. Renal tissue was harvested at the end of the experiment and immediately fixed in Karnovsky fixative. Ten random capillaries in the renal cortex were captured using electron microscope imaging (Tecnai 12G2, Fei company, with a VALETA side entry camera) by an investigator blinded to group allocation. Subsequently, images were analyzed for signs of endothelial injury and activation, including luminal membrane blebs, vacuoles, endothelial gaps and endothelial detachment. Detailed information can be found in the Additional file 1.

Plasma and urinary analyses

Arterial blood was collected in EDTA tubes at baseline, 60 after initiation of CPB (60 min CPB), and 60 min after weaning from CPB (60 min post-CPB) and urine samples were obtained one hour after weaning of CPB (60 min post-CPB). Urinary levels of
neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) and plasma levels of NGAL, KIM-1, creatinine, thrombin–antithrombin complex (TAT), soluble thrombomodulin (sTM), von Willebrand Factor (vWF) and interleukin-6 (IL-6) were measured with ELISA (Cloud-Clone Corporation, Wuhan, Hubei, China) in accordance to the manufacturer. Detailed information can be found in the Additional file 1.

Immunohistochemical analyses
Renal tissue was fixed in 4% formalin and embedded in paraffin. Immunohistochemical staining was performed for assessment of glomerular and tubulointerstitial neutrophil infiltration by anti-myeloperoxidase (MPO; 1:50, Abcam, Cambridge, UK) [14, 27] and for assessment of fibrin-stained thrombi deposition by Martius, Scarlet and Blue (MSB) staining. The investigator performing the analysis was blinded to group allocation. Detailed information can be found in the Additional file 1.

Gene expression
Total RNA was extracted from 10–30 mg frozen kidney tissue and isolated using the RNeasy mini kit (Qiagen, Venlo, The Netherlands), as previously described [15]. The following genes were used for quantitative PCR: KIM-1, NGAL, ICAM-1, VCAM-1, E-selectin, P-selectin and PAR1 (Applied Biosystems, Foster City, CA). ΔcT was calculated and mRNA expression levels were normalized to the housekeeping gene Tfrc.

Protein expression
Frozen kidney tissue was homogenized to obtain cellular protein fractions for western blot analysis as described previously [15, 26]. Protein expression of uncleaved PAR1 was analyzed using anti-PAR1/Thrombin Receptor (25 µg protein, 1:200, ab32611, Abcam, USA). Immunoblots were quantified by densitometric analysis of films (ImageQuant TL, v8.1, GE Healthcare, USA). Signal was normalized to glyceraldehyde 3-phosphate dehydrogenase protein expression (GAPDH; 1:5000, No. 2118, Cell Signaling Technology, USA).

Statistical analysis
All data are expressed as median (full range) or mean± standard deviation (SD) and analyzed using GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA). Sample size was calculated based on previous rat experiments in which cardiopulmonary bypass induced a decrease in cremaster perfused capillaries from 9.2 to 5.5±1.5 perfused vessels per recording [14, 15]. Sample size for renal perfusion measurements were based on pilot experiments in which cardiopulmonary bypass induced a decrease in renal perfusion from of 95 to 48±12. Using an alpha of 0.05 and a power of 0.90, a sample size of 8 per group was required for cremaster perfusion measurements and a sample size of 15 was required for renal measurements. Normality of distribution was tested with the Shapiro–Wilk test. Time-dependent differences were analyzed with two-way ANOVA with repeated measures and Bonferroni post hoc analysis. Two-sided Mann–Whitney U- and Wilcoxon tests were used to evaluate differences in-between groups and within groups, respectively. p values < 0.05 were considered as statistically significant.
Results

Hemodynamics and blood gas analysis

All animals completed the experimental protocol. Rats weighed $400 \pm 8$ and $401 \pm 10$ g for control and aprotinin-treated groups, respectively ($p = 0.71$). Cardiopulmonary bypass was associated with reduced mean arterial pressure (Fig. 1b, median (full range), 88 (62–111) to 72 (50–103) mmHg, $p = 0.02$) and hematocrit levels (Fig. 1c, 39 (36–42) to 22 (18–37) %, $p < 0.0001$), which remained altered in the first hour after weaning from CPB ($p = 0.0001$ and $p < 0.0001$, respectively). Moreover, CPB resulted in a reduction in heart rate (375 (343–408) to 320 (257–371) bpm, $p = 0.0001$) and temperature (36.5 (35.3–37.7) to 35.0 (33.4–35.7) °C, $p < 0.0001$). Also, onset of CPB reduced bicarbonate levels (24 (19–27) to 18 (14–21) $p < 0.0001$) and a reduction in pH was observed immediately after weaning from CPB (7.4 (7.3–7.5) to 7.2 (7.1–7.4), $p < 0.0001$), whereas oxygen saturation and partial pressures of carbon dioxide and oxygen remained unaltered.

Aprotinin did not affect mean arterial pressure or hematocrit levels throughout the experiment (Fig. 1b, c). Moreover, pH ($p = 0.6$), base excess ($p > 0.9$), partial pressures of carbon dioxide ($p > 0.9$) and oxygen ($p > 0.9$) were comparable between CPB controls and aprotinin-treated animals. There were no differences in the use of isoflurane anesthesia ($p = 0.71$), phenylephrine ($p = 0.63$), CPB flow rates ($p > 0.9$) or body temperature ($p = 0.64$) between groups (data not shown).

Cremaster perfusion

Onset of CPB was associated with a 2.5-fold reduction in the number of perfused vessels (15 (10–16) to 6 (2–10) perfused vessels per recording, $p < 0.0001$; Fig. 2a), and a 2.6-fold increase in the number of non-perfused vessels (3 (2–5) to 8 (5–11) non-perfused vessels per recording, $p < 0.0001$; Fig. 2b) compared with baseline measurements in CPB control rats. Microcirculatory perfusion remained impaired in the first hour after weaning from CPB. The number of intermittently perfused vessels remained stable throughout the experiment (0 (0–0) to 0 (0–0) intermittently perfused vessels per recording, baseline to 60 min post-CPB, $p > 0.9$).

In aprotinin-treated animals, onset of CPB was associated with a 1.5-fold reduction in the number of perfused vessels (15 (11–16) to 12 (7–15) perfused vessels per recording, $p = 0.0002$; Fig. 2a) and a 1.5-fold increase in number of non-perfused vessels (2 (1–3) to 3 (1–7) non-perfused vessels per recording, $p = 0.0002$; Fig. 2b). This reduction was less profound compared to untreated CPB animals (15 (11–16) to 12 (7–15) vs. 15 (10–16) to 6 (2–10) perfused vessels per recording, CPB + AP vs. CPB, $p < 0.0001$; 2 (1–3) to 3 (1–7) vs. 3 (2–5) to 8 (5–11) non-perfused vessels per recording, CPB + AP vs. CPB, $p < 0.0001$). No differences in baseline microcirculatory perfusion nor intermittently perfused vessels were observed between groups.

Renal perfusion

CPB did not affect renal blood volume ($A$) in control animals throughout the study period (Fig. 2c, 149 (56–410) vs. 123 (38–540) a.u., $p > 0.9$, 60 min post-CPB vs. baseline). However, a reduction in renal vascular filling velocity ($\beta$) was observed immediately after weaning from CPB compared with baseline measurements (1.3 (0.7–1.9) to
0.9 (0.5–1.2) per sec, \( p < 0.0001 \), and remained decreased one hour after weaning from CPB (Fig. 2d, 0.7 (0.4–1.4), \( p < 0.0001 \), 60 min post-CPB). Overall, CPB reduced renal perfusion one hour after weaning from CPB compared with baseline measurements in untreated CPB animals (Fig. 2e, 202 (67–599) to 129 (31–292) a.u./sec, \( p = 0.03 \), baseline to 60 min post-CPB).

Aprotinin treatment did not affect renal blood volume (\( p > 0.9 \)), filling velocity (\( p = 0.52 \)) nor renal perfusion (\( p > 0.9 \)) throughout the course of the experiment compared with untreated CPB animals (Fig. 2). Estimate of renal perfusion was significantly reduced in both CPB groups compared to sham animals 60 min post-CPB (237 (197–645) vs. 129 (31–292) a.u./s, sham vs CPB control, \( p = 0.044 \); (237 (197–645) vs. 96 (35–520) a.u./sec, sham vs CPB + AP, \( p = 0.03 \), RM ANOVA (Additional file 2: Figure S2)).

**Renal edema and fluid requirements**

Renal wet/dry weight ratio was reduced in rats treated with aprotinin compared to untreated CPB rats one hour after weaning from CPB (Fig. 3b, 4.4 ± 0.2 vs. 4.6 ± 0.2, CPB + AP vs. CPB, \( p = 0.01 \)), indicative of reduced edema formation. Aprotinin-treated rats required 50% less fluids during and after CPB compared with untreated CPB animals (Fig. 3b, 4 ± 3 vs. 8 ± 3 ml, CPB + AP vs. CPB, \( p = 0.005 \)).

**Renal endothelial architecture, neutrophil infiltration and fibrin deposition**

Renal endothelial ultrastructure was better preserved in rats treated with aprotinin compared to untreated animals (Fig. 4). Aprotinin reduced endothelial vacuolization (Fig. 4e, 3.3 ± 0.9 vs. 6.4 ± 2.0 vacuoles/capillary cross section, CPB + AP vs. CPB, \( p = 0.0005 \)) and membrane blebbing (Fig. 4f, 6.9 ± 1.7 vs. 14.3 ± 3.1 blebs per capillary cross section, CPB + AP vs. CPB, \( p < 0.0001 \)). Moreover, aprotinin treatment reduced renal endothelial gap formation (Fig. 4g, 0.5 ± 0.5 vs. 3.1 ± 1.4 gaps per capillary cross section, CPB + AP vs. CPB, \( p < 0.0001 \)) and endothelial cell detachment from basement membrane (Fig. 4h,
1.0 ± 0.6 vs. 2.7 ± 1.2 detachments per capillary cross section, CPB + AP vs. CPB, p = 0.0006).

Moreover, aprotinin treatment reduced tubulointerstitial neutrophil influx by 1.7-fold compared to untreated CPB rats (Fig. 4g–i, 30.7 ± 22.1 vs. 53.2 ± 17.2 tubulointerstitial neutrophil influx per section, CPB + AP vs. CPB, p = 0.009). Aprotinin treatment did not affect glomerular neutrophil infiltration (Fig. 5a–c, 1.4 ± 1.1 vs. 1.2 ± 0.6 neutrophil influx per glomerulus, CPB + AP vs. CPB, p = 0.73), fibrin-stained glomerular thrombi (Fig. 5d–f, 0.049 ± 0.043 vs. 0.073 ± 0.058 MSB + foci per glomerulus, CPB + AP vs. CPB, p = 0.33), nor fibrin-stained tubulointerstitial thrombi (Fig. 5j–l, 1.3 ± 1.1 vs. 1.4 ± 1.0 MSB + foci per section, CPB + AP vs. CPB, p = 0.8) compared to untreated CPB rats.

Coagulation and inflammatory signaling

CPB increased circulating levels of IL-6, vWF, sTM and TAT, which further increased in the first hour after weaning from CPB (Table 1). Aprotinin did not affect circulating levels of these molecules at baseline nor during the course of the experiment (Table 1). Moreover, no differences in renal adhesion molecule expression (ICAM-1, VCAM-1, E-selectin and P-selectin gene expression) was observed one hour after weaning from CPB between groups (Table 1). Also, no differences in PAR1 gene nor protein levels were observed between groups (Table 1).

Renal injury

CPB was associated with increased plasma and urine concentrations of renal injury markers NGAL, KIM-1 and creatinine one hour after weaning from CPB (Table 1). Aprotinin did not affect plasma or urine concentrations of renal injury markers nor renal injury gene expression levels (Table 1). The elevation of plasma renal injury markers was observed in both CPB groups 60 min post-CPB, however, not in sham animals (Additional file 2: Figure S3).

Discussion

In the present study, we demonstrate that aprotinin administration preserved renal endothelial structure and reduced renal edema formation following experimental CPB. This was associated with reduced fluid resuscitation requirements and restoration of cremaster microcirculatory perfusion. These findings are important as they emphasize on the broad spectrum of actions of aprotinin. Besides prevention of blood loss and preservation of platelet function, we showed that aprotinin preserved renal endothelial ultrastructure following CPB. Despite its endothelial protective effect, aprotinin administration was however not sufficient to preserve renal perfusion nor reduce renal injury markers the first hour after weaning from CPB.

Previously, we showed that plasma from patients undergoing cardiac surgery with CPB resulted in loss of in vitro endothelial barrier function [28]. This plasma-induced endothelial hyperpermeability continued in the first postoperative days and correlated with in vivo microcirculatory perfusion disturbances [29]. These results emphasize capillary leakage as underlying mechanism of CPB-induced microcirculatory perfusion disturbances and AKI. Additionally, supporting this hypothesis, we previously showed
that therapeutic inhibition of capillary leakage by imatinib and vasculotide, drugs that improve vascular barrier function, improved cremaster microcirculatory perfusion and reduced organ edema following experimental CPB [14, 15]. Despite these promising findings, vasculotide was effective in reducing only pulmonary edema but not renal edema. In contrast, imatinib was found to reduce renal edema and markers of renal injury, however, its use is associated with a wide range of side effects and is registered for the treatment of chronic myeloid leukemia, which may hamper its implementation in cardio-surgical setting.

Aprotinin is suggested to reduce capillary leakage and is of interest as it is already used in cardiac surgery to inhibit hyperfibrinolysis. In patients undergoing cardiac surgery, aprotinin is thought to decrease pulmonary edema [30]. In experimental CPB, aprotinin reduced myocardial edema and fluid requirements [31]. Our data confirm these results as we demonstrated that aprotinin administration maintained renal endothelial structure and prevented renal edema formation. Additionally, less fluids were required following aprotinin administration to maintain adequate pump flow. These results suggest that aprotinin has endothelial barrier protective effects resulting in less capillary leakage and edema formation in kidneys during experimental CPB.

As a non-specific serine protease inhibitor, aprotinin operates via numerous mechanisms [32]. Aprotinin can prevent thrombin from cleaving and activating PAR1 [21–24]. Thrombin regulates endothelial permeability, vascular tone, leukocyte trafficking and inflammation, formation of new vessels, and hemostasis. PAR1 is the principal receptor for thrombin and is shown to regulate endothelial permeability. In the present study, onset of CPB resulted in thrombin generation as assessed by thrombin–antithrombin complex formation. However, we did not find an effect of aprotinin on renal PAR1 expression. This might be due to the lack of available antibodies to assess the activation status of PAR1. As a consequence, only uncleaved PAR1 could be determined. However, we cannot rule out that aprotinin activated alternative mechanisms preserving endothelial barrier function, as it has been implicated that aprotinin inhibits plasma leakage induced by kallikrein. Moreover, aprotinin has anti-inflammatory properties. In previous studies, aprotinin reduced thrombin-induced IL-6 secretion [23] and TNFα-induced ICAM-1 and VCAM-1 expression [21–24] by endothelial cells in vitro. In addition, aprotinin inhibited leukocyte extravasation in rats [33]. In line, we found reduced

![Fig. 3](image-url)
tubulointerstitial neutrophil extravasation in aprotinin-treated animals compared to control animals. Interestingly however, circulating inflammatory mediators were comparable between aprotinin-treated and untreated rats. This contrasting finding could result
from dose-dependent actions of aprotinin. Aprotinin seems to be more effective at high doses and when given during reperfusion [33], which may potentially partly be explanatory for the lack of preservation of renal perfusion and function in our study. Collectively, aprotinin seems to target multiple mechanisms and the effects on the endothelium remain complex and need further investigation.

As a consequence of capillary leakage, we hypothesized the development of microcirculatory perfusion disturbances and AKI [14, 15]. Patients undergoing cardiac surgery with CPB show sublingual microcirculatory perfusion disturbances [7, 8] and it is suggested that these microcirculatory perfusion disturbances play a crucial role in the development of AKI [34, 35]. The question remains whether sublingual measurements can be translated to other organs, such as kidneys. The present study showed impaired renal perfusion following CPB which was indeed associated with by increased markers of renal injury. As aprotinin was not sufficient to preserve renal perfusion, the
hypothesized causality between renal perfusion disturbances and renal injury following CPB could not be confirmed. Interestingly, the present study demonstrates that aprotinin administration restored cremaster microcirculatory, but not renal perfusion. Previously, these differences between microvascular beds was observed by our group in a cell-type specific effect of plasma-induced endothelial hyperpermeability, which was more severe in pulmonary endothelial cells compared to renal endothelial cells [29]. In line with these findings, we observed that aprotinin more effectively reduced pulmonary edema compared to renal edema (data not shown). Another explanation is that cremaster perfusion was specifically measured in the capillaries, while renal perfusion analysis included vessels of all sizes. The effects of aprotinin on renal perfusion are however scarcely studied. In patients undergoing cardiac surgery with CPB, renal plasma flow decreased following CPB and was not affected by aprotinin administration [36, 37]. Even though the effects of aprotinin on renal perfusion during CPB requires further investigation, these data implicate organ specific effects of aprotinin.

Aprotinin was reintroduced in 2017, 10 years after it was taken of the market. Conflicting results have been reported concerning the effect of aprotinin during cardiac surgery
on postoperative morbidity, including renal function. [38, 39] However, validity was questioned, as most studies that reported increased postoperative morbidity risk following aprotinin administration were subjected to sources of bias and were not designed to look at safety. When reviewing randomized placebo-controlled trials, aprotinin use during cardiac surgery was not associated with increased risk of postoperative morbidity, including renal injury, or mortality [40]. In accordance, we did not observe deleterious effects of aprotinin administration on renal function in our rat CPB model.

Controversy exists concerning the effect of CPB on the development of AKI. Large randomized trials revealed no differences on occurrence of postoperative AKI between off-pump and on-pump coronary artery bypass grafting, indicating that in particular non-CPB factors may contribute to postoperative AKI [41, 42]. However, these findings should be placed into perspective as most of these trials were subjected to imbalanced exclusion of patients assigned to off-pump surgery and primarily focused on mortality rates and renal replacement therapy as outcome measures. Renal replacement therapy as outcome is not representative for the prevalence of CPB-associated renal injury, as the incidence of AKI requiring dialysis is usually low (up to 4%), whereas less severe forms of postoperative renal dysfunction, while still being clinically relevant, are observed in 5 to 53% of the patients [43–45]. When interpreting these trials, it is important to consider that the incidence of AKI depends on studied cardiac surgical population, preoperative renal function status, and criteria used to define acute kidney injury. In addition, magnitude of tubular injury and occurrence of postoperative AKI appears independently associated with duration of CPB, duration of low oxygen delivery (DO2) during CPB, and degree of rewarming [46, 47].

This study has limitations. We choose to study a clinically relevant dose (reflecting a full Hammersmith protocol) based on previous studies that showed that patients receiving full Hammersmith aprotinin protocol showed significant reductions in circulating interleukin levels. However, in our study, aprotinin was not continuously infused nor added to CPB prime solution and may therefore have not been sufficient to suppress the systemic inflammatory response, potentially the consequence of first pass effect. Nevertheless, based on our observation in the cremaster muscle, a biological effect of aprotinin was clearly present. Moreover, a potential beneficial effect of aprotinin administration on renal function may have been masked by the decrease in blood pressure following CPB and the relatively short follow-up period following weaning from CPB. Also, our extracorporeal circuit was primed with hydroxyethyl starch, a colloid solution. Although concerns have been raised concerning the effect of colloids on renal function, the use of modern hydroxyethyl starch solutions in surgical settings, including cardiac surgery, was not associated with increased risk of acute kidney injury [40]. Moreover, when interpreting our data, one should take into consideration that cardiac surgery associated renal injury is multifactorial. Within our experimental set-up, we focused primarily on CPB-associated renal perfusion disturbances as main contributor to AKI. Aside from renal perfusion disturbances, also CPB-induced hemolysis through mechanical destruction of erythrocytes caused by contact of blood with the bypass circuit and cardiotomy suction, was not taken into account [48]. This was partly avoided, as sternotomy and cardiotomy suction were not performed in our experimental CPB model. Moreover, post-CPB concentrations of NGAL did not differ between studied CPB groups, which is suggested to
correlate with both AKI and hemolysis in the clinical setting [49]. However, although sternotomy and cardioplegic arrest were avoided, our CPB model did enable discontinuation of ventilation and ensures systemic oxygenation while minimizing cardiac blood flow and pulse pressure, thereby mimicking true CPB effect. This is in accordance with our findings that an additional group of sham rats, that received similar anesthetic and surgical procedures, did not show described perfusion disturbances and elevation of renal injury markers during our experimental study period (Additional file 2).

Conclusions

CPB impairs renal endothelial integrity and is associated with renal edema and renal microcirculatory perfusion disturbances. Our study revealed that although aprotinin protects renal endothelial integrity and reduced renal edema, this strategy was not sufficient to preserve renal perfusion nor reduce renal injury during the first hour following CPB. The findings of our study highlight the importance of the development of new therapeutic interventions to improve renal perfusion, particularly in the setting of cardiac surgery with CPB.

Abbreviations

AKI: Acute kidney injury; AP: Aprotinin; CPB: Cardiopulmonary bypass; ELISA: Enzyme-linked immunosorbent assay; ICAM-1: Intercellular adhesion molecule 1; IL-6: Interleukin-6; Kg: Kilogram; KIM-1: Kidney injury molecule-1; Min: Minutes; MPO: Myeloperoxidase; MSB: Martius, Scarlet and Blue; NGAL: Neutrophil gelatinase-associated lipocalin; PAR1: Protease-activated receptor 1; PBS: Phosphate buffered solution; Sec: Second(s); sTM: Soluble thrombomodulin; TAT: Thrombin–antithrombin complex; TNFα: Tumor necrosis factor alpha; VCAM-1: Vascular cell adhesion molecule 1; vWF: Von Willebrand Factor.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40635-021-00393-9.

Additional file 1: Additional methods.

**Additional file 2: Figure S1.** Mean arterial pressure (B) and hematocrit levels (C) in rats during and following cardiopulmonary bypass (CPB; white boxes; n=15), CPB with aprotinin treatment (CPB+AP; red boxes; n=15), or sham rats (Sham; grey boxes n=9). Boxes and whiskers represent median, interquartile and full range, * p < 0.05 CPB vs. CPB baseline, # p < 0.05 CPB groups vs. sham. Figure S2. Renal blood volume (A), renal vascular filling velocity (B), and estimate of renal perfusion (C) measured in the right renal cortex using contrast enhanced ultrasound in sham rats (Sham; grey boxes; n=9), rats undergoing cardiopulmonary bypass (CPB; white boxes; n=15) or rats undergoing CPB with aprotinin treatment (CPB+AP; red boxes; n=15). Boxes and whiskers represent median, interquartile and full range, * p < 0.05 CPB vs. CPB baseline, # p < 0.05 CPB vs. sham. Figure S3. Plasma concentrations of renal injury molecules NGAL (A), KIM-1 (B), and creatinine (C) measured 1 hour (1h) after weaning from CPB. Data are presented as mean ± standard deviation. A black bar represents p < 0.05 CPB vs sham. CPB, cardiopulmonary bypass; NGAL, neutrophil gelatinase-associated lipocalin; KIM-1, kidney injury molecule-1.

Acknowledgements

Not applicable.

Authors’ contributions

N.A.M.D., C.E.v.B., M.v.M., J.M., and C.B. conception and design of research. N.A.M.D., A.L.I.v.L., J.E.P., N.N.v.d.W, and C.E.v.d.B performed experiments and analyzed data. N.A.M.D., C.E.v.B., A.B.A.V., H.W.N., M.G.V., P.L.H. and C.B. interpreted results of experiments. N.A.M.D., C.E.v.B. and C.B. drafted manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Dutch Heart Foundation [Grant number 2016T064 to N.A.M.D.], CSL-Behring [Prof Heimburger Young Investigator Grant to N.A.M.D.], the Dutch Society of Anaesthesiology [Young Investigator Grant 2014 to M.v.M.], the European Society of Anaesthesiology [Research Project Grant 2016 to C.E.v.d.B.], the European Society of Intensive Care Medicine [Levi-Montalcini Award 2017 to C.E.v.d.B.], the Dutch Society of Anaesthesiology [Young Investigator Grant 2017 to C.E.v.d.B.], and the Dutch Research Council [Yeni 2019 to C.E.v.d.B.]. The remaining authors are financially supported by their department.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
All procedures were approved by the Institutional Animal Care and Use Committee of the VU University, the Netherlands (Animal welfare number: AVD1140020172144; local protocol number: 2144-ANES-17-01), and conducted following the EU Directive (2010/63/EU) on the protection of vertebrate animals used for experimental and other scientific purposes.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no financial or non-financial competing interest.

Author details
1. Department of Anesthesiology, Experimental Laboratory for Vital Signs, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. 2. Department of Cardiothoracic Surgery, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. 3. Department of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. 4. Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Critical Care Medicine, University Medical Center Groningen, Groningen, The Netherlands. 6. Department of Medical Biology, Electron Microscopy Centre Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 7. Department of Pathology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. 8. Department of Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. 9. Department of Intensive Care Medicine, Laboratory for Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Received: 9 February 2021   Accepted: 4 May 2021

Published online: 25 June 2021

References
1. Fuhrman DY, Kellum JA (2017) Epidemiology and pathophysiology of cardiac surgery-associated acute kidney injury. Curr Opin Anaesthesiol 30(1):60–65
2. Amini S, Najafi MN, Karrari SP et al (2019) Risk factors and outcome of acute kidney injury after isolated CABG surgery: a prospective cohort study. Braz J Cardiovasc Surg 34(1):70–75
3. Thiele RH, Isbell JM, Rosner MH (2015) AKI associated with cardiac surgery. Clin J Am Soc Nephrol 10(13):500–514
4. Chew STH, Hwang NC (2019) Acute kidney injury after cardiac surgery: a narrative review of the literature. J Cardiothorac Vasc Anesth 33(4):1122–1138
5. Ortega-Loubon C, Fernández-Molina M, Carrascal-Hinojal Y, Fulquet-Carreras E (2016) Cardiac surgery-associated acute kidney injury. Ann Card Anaesth 19(4):687–698
6. O’Neal JB, Shaw AD, Billings FT (2016) Acute kidney injury following cardiac surgery: current understanding and future directions. Crit Care 20(1):187
7. Koning NJ, Atasever B, Vonk ABA, Boer C (2014) Changes in microcirculatory perfusion and oxygenation during cardiac surgery with or without cardiopulmonary bypass. J Cardiothor Vasc Anesth 28(5):1331–1340
8. Dekker NAM, Veerhoek D, Koning NJ et al (2019) Postoperative microcirculatory perfusion and endothelial glycocalyx shedding following cardiac surgery with cardiopulmonary bypass. Anaesthesia 74(5):609–618
9. Ince C (2014) The central role of renal microcirculatory dysfunction in the pathogenesis of acute kidney injury. Nephron Clin Pract 127(1–4):124–128
10. Ranucci M, Johnson I, Willcox T et al (2018) Goal-directed perfusion to reduce acute kidney injury: a randomized trial. J Thorac Cardiovasc Surg 156(5):1918–1927
11. Landenmyr L, Bragadottir G, Hjärpe A, Redfors B, Ricksten SE (2019) Impact of cardiopulmonary bypass flow on renal oxygenation in patients undergoing cardiac operations. Ann Thorac Surg 107(2):505–511
12. Jongman RM, Zijlstra JG, Kok WF et al (2014) Off-pump CABG surgery reduces systemic inflammation compared with on-pump surgery but does not change systemic endothelial responses: a prospective randomized study. Shock 42(2):121–128
13. Hirlerman E, Larson DF (2008) Cardiopulmonary bypass and edema: physiology and pathophysiology. Perfusion 23(6):311–322
14. Koning NJ, de Lange F, van Meurs M et al (2018) Reduction of vascular leakage by imatinib is associated with preserved microcirculatory perfusion and reduced renal injury markers in a rat model of cardiopulmonary bypass. Br J Anaesth 120(6):1165–1175
15. Dekker NAM, van Meurs M, van Leeuwen AL et al (2018) Vasculotide, an angiotropin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats. Br J Anaesth 121(S):1041–1051
16. Scarscia G, Rotunno C, Simone S et al (2017) Acute kidney injury in high-risk cardiac surgery patients: roles of inflammation and coagulation. J Cardiovasc Med 18(5):359–365
17. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW (1999) Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 96(20):11189–11193
18. Siller-Matula JM, Schwanes M, Blann A, Mannhalter C, Jilma B (2011) Thrombin as a multi-functional enzyme: Focus on in vitro and in vivo effects. Thromb Hemost 106(6):1020–1033
19. Landis C (2007) Why thrombin PAR1 receptors are important to the cardiac surgical patient. J Extra Corpul Technol 39:305–307
20. Wachtfogel YT, Kucich U, Hack CE et al (1993) Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106(1):1–9
21. Day JR, Haskard DO, Taylor KM, Landis RC (2006) Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation. Ann Thorac Surg 81:619–624
22. Coughlin SR (2000) Thrombin signaling and protease-activated receptors. Nature 407:258–264
23. Day JR, Taylor KM, Lidingo EA et al (2006) Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 131(1):21–27
24. Asimakopoulos G, Lidingo EA, Mason J, Haskard DO, Taylor KM, Landis RC (2001) Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 122:123–128
25. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6)e1000412
26. van den Brem CE, Boly CA, Bulte CS et al (2016) Myocardial perfusion and function are distinctly altered by sevoflurane anaesthesia in diet-induced prediabetic rats. J Diabetes Res 2016:5205631
27. Aslan A, van den Heuvel MC, Stegeman CA et al (2018) Kidney histopathology in lethal human sepsis. Crit Care 22(1):359
28. Koning NJ, Overmars MA, van den Brem CE et al (2016) Endothelial hyperpermeability after cardiac surgery with cardiopulmonary bypass as assessed using an in vitro bioassay for endothelial barrier function. Br J Anaesth 116(2):223–232
29. Dekker NAM, van Leeuwen ALI, van Strien WWJ et al (2019) Microcirculatory perfusion disturbances following cardiac surgery with cardiopulmonary bypass are associated with in vitro endothelial hyperpermeability and increased angiopoietin-2 levels. Crit Care 23(1):117
30. Lazaro HL, Bao Y, Tanziello L et al (2005) Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg 20(6):519–523
31. Khan TA, Bianchi C, Araujo E et al (2005) Aprotinin preserves cellular junctions and reduces myocardial edema after regional ischemia and cardioplegic arrest. Circulation 112(Suppl I):I1196-201
32. McEvoy MD, Reeves ST, Reeves JG, Spinale FG (2007) Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg 105(4):949–962
33. Asimakopoulos G, Thompson SP, Nounghargh S et al (2000) An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 120(2):361–369
34. Harrois A, Grillot N, Figueiredo S, Duranteau J (2018) Acute kidney injury is associated with a decrease in cortical renal perfusion during septic shock. Crit Care 22:161
35. Schneider AG, Goodwin MD, Schelleman A, Bailey M, Johnson L, Bellomo R (2013) Contrast-enhanced ultrasound to evaluate changes in renal cortical perfusion around cardiac surgery: a pilot study. Crit Care 17(4):R138
36. Schweizer A, Höhn L, Morel DR, Kalangos A, Licker M (2008) Aprotinin does not impair renal hemodynamics and function after cardiac surgery. Br J Anaesth 94(1):16–22
37. Fergusson DA, Hébert PC, Mazer CD et al (2008) BART Investigators: a comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358(22):2319–2331
38. Benedetto U, Altman DG, Gery S, et al. (2018) ART (Arterial Revascularization Trial) Investigators. Safety of perioperative aprotinin administration during isolated coronary artery bypass surgery: insights from the ART (Arterial Revascularization Trial). J Am Heart Assoc 7(5):e007570
39. Sedraian A, Treare T, Elefteriades JA (2004) Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized controlled trials. J Thorac Cardiovasc Surg 128(3):442–448
40. Vives M, Callejas R, Duque P et al (2016) Modern hydroxyethyl starch and acute kidney injury after cardiac surgery: a prospective multicenter cohort. Br J Anaesth 117(4):458–463
41. Lamy A, Devereaux PJ, Prabhakaran D et al. (2013) Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med 368(13):1179–1188
42. Diegeler A, Bogermann J, Kappert U et al (2013) Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med 368(3):1189–1198
43. Vives M, Hernandez A, Parramon F, Estanyol N, Pardina B, Muñoz A, Alvarez P, Hernandez C, Vives M et al (2019) Acute kidney injury after cardiac surgery: prevalence, impact and management challenges. Int J Nephrol Renovasc Dis 12:153–166
44. Hu J, Chen R, Liu S et al (2016) Global incidence and outcomes of adult patients with acute kidney injury after cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 30:82–89
45. Lagny M, Jouret F, Koch J et al (2015) Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. BMC Nephrol 16:76
46. Oshita T, Hiraoka A, Nakajima K et al (2020) A better prediction of acute kidney injury after cardiac surgery: the largest area under the curve below the oxygen delivery threshold during cardiopulmonary bypass. J AHA 9(15):e015566
47. Xu S, Liu L, Wu Z et al (2019) Cardiopulmonary bypass time is an independent risk factor for acute kidney injury in emergent thoracic aortic surgery: a retrospective cohort study. J Cardiothorac Surg 14(1):90
48. Wetz AJ, Richardt EM, Schotola H et al (2017) Haptoglobin and free haemoglobin during cardiac surgery—is there a link to acute kidney injury? Anaesth Intensive Care 45(1):58–66

49. Mamikonian LS, Mamo LB, Smith PB et al (2014) Cardiopulmonary bypass is associated with hemolysis and acute kidney injury in neonates, infants, and children. Pediatr Crit Care Med 15(3):e111–e119

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.